Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + temsirolimus after first-line bevacizumab + interferon in advanced renal cell carcinoma
2010-020664-38Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bevacizumab and temsirolimus in renal cell carcinoma (RCC), sponsored by HeCOG. Primary endpoints: 6-month progression-free survival and progression-free survival. Started Oct 2010; status: terminated.
02
Drugs
bevacizumabtemsirolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2010-020664-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020664-38.